The gam­ma delta T cell gam­bit in­spires a small Lon­don biotech start­up with big ideas

If you run through the whole gamut of cell ther­a­pies be­ing worked on in can­cer re­search these days, gam­ma delta T cells aren’t like­ly to fig­ure promi­nent­ly in your re­view. But for years now Adri­an Hay­day, who runs labs at The Fran­cis Crick In­sti­tute and King’s Col­lege Lon­don, has been fas­ci­nat­ed by their un­usu­al abil­i­ty to pen­e­trate in­to tis­sue, mak­ing them po­ten­tial ther­a­peu­tic can­di­dates.

And now, with the ex­plo­sion of im­muno-on­col­o­gy re­search work, some mar­quee re­search play­ers have set out to take Hay­day’s work — along with con­tri­bu­tions by Oliv­er Nuss­baumer — in­to the clin­ic, seed­ing a start­up which will now nav­i­gate its way through about 18 months of pre­clin­i­cal work iden­ti­fy­ing a lead pro­gram that can be tak­en in­to a hu­man study.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.